Treatment with PD-CLD-Fc also resulted in a statistically significant reduction in the severity of lung pathology as measured by a composite index of alveolitis, pneumocyte hyperplasia, vasculitis, interstitial hyperplasia, lesion extent, and bronchitis (Fig. 5D). This evidence concerns the gene SLC26A3 and bronchial disorder.